OBJECTIVES/HYPOTHESIS: To determine the factors associated with longitudinal patient-reported dysphagia as measured by the MD Anderson Dysphagia Inventory (MDADI) in locoregionally advanced oropharyngeal carcinoma (OPC) survivors treated with split-field intensity modulated radiotherapy (IMRT). STUDY DESIGN: Retrospective patient analysis. METHODS: A retrospective analysis combined data from three single-institution clinical trials for stage III/IV head and neck carcinoma. According to trial protocols, patients had prospectively collected MDADI at baseline, 6, 12, and 24 months after treatment. OPC patients with baseline and at least one post-treatment MDADI were included. Longitudinal analysis was completed with multivariate linear mixed effects modeling. RESULTS: There were 116 patients who met inclusion criteria. Mean baseline MDADI composite was 88.3, dropping to 73.8 at 6 months, and rising to 78.6 and 83.3 by 12 and 24 months, respectively (compared to baseline, all P < .0001). Tumor stage and smoking status were significant predictors of longitudinal MDADI composite scores. Patients with T1, T2, and T3 tumors had 15.9 (P = .0001), 10.9 (P = .0049), and 7.5 (P = .0615), respectively, higher mean MDADI composite than those with T4 tumors, and current smokers had a 9.4 (P = .0007) lower mean MDADI composite than never smokers. CONCLUSIONS: Patients report clinically meaningful dysphagia early after split-field IMRT for locoregionally advanced OPC that remains apparent 6 months after treatment. MDADI scores recover slowly thereafter, but remain depressed at 24 months compared to baseline. Higher tumor stage and smoking status are important markers of patient-reported function through the course of treatment, suggesting these are important groups for heightened surveillance and more intensive interventions to optimize swallowing outcomes. LEVEL OF EVIDENCE: 4 Laryngoscope, 127:842-848, 2017.
OBJECTIVES/HYPOTHESIS: To determine the factors associated with longitudinal patient-reported dysphagia as measured by the MD Anderson Dysphagia Inventory (MDADI) in locoregionally advanced oropharyngeal carcinoma (OPC) survivors treated with split-field intensity modulated radiotherapy (IMRT). STUDY DESIGN: Retrospective patient analysis. METHODS: A retrospective analysis combined data from three single-institution clinical trials for stage III/IV head and neck carcinoma. According to trial protocols, patients had prospectively collected MDADI at baseline, 6, 12, and 24 months after treatment. OPC patients with baseline and at least one post-treatment MDADI were included. Longitudinal analysis was completed with multivariate linear mixed effects modeling. RESULTS: There were 116 patients who met inclusion criteria. Mean baseline MDADI composite was 88.3, dropping to 73.8 at 6 months, and rising to 78.6 and 83.3 by 12 and 24 months, respectively (compared to baseline, all P < .0001). Tumor stage and smoking status were significant predictors of longitudinal MDADI composite scores. Patients with T1, T2, and T3 tumors had 15.9 (P = .0001), 10.9 (P = .0049), and 7.5 (P = .0615), respectively, higher mean MDADI composite than those with T4 tumors, and current smokers had a 9.4 (P = .0007) lower mean MDADI composite than never smokers. CONCLUSIONS:Patients report clinically meaningful dysphagia early after split-field IMRT for locoregionally advanced OPC that remains apparent 6 months after treatment. MDADI scores recover slowly thereafter, but remain depressed at 24 months compared to baseline. Higher tumor stage and smoking status are important markers of patient-reported function through the course of treatment, suggesting these are important groups for heightened surveillance and more intensive interventions to optimize swallowing outcomes. LEVEL OF EVIDENCE: 4 Laryngoscope, 127:842-848, 2017.
Authors: Shao Hui Huang; Bayardo Perez-Ordonez; Ilan Weinreb; Andrew Hope; Christine Massey; John N Waldron; John Kim; Andrew J Bayley; Bernard Cummings; B C John Cho; Jolie Ringash; Laura A Dawson; Lillian L Siu; Eric Chen; Jonathan Irish; Patrick Gullane; Angela Hui; Fei-Fei Liu; Xiaowei Shen; Wei Xu; Brian O'Sullivan Journal: Oral Oncol Date: 2012-08-20 Impact factor: 5.337
Authors: Catherine F Sinclair; Nancy L McColloch; William R Carroll; Eben L Rosenthal; Reneé A Desmond; J Scott Magnuson Journal: Arch Otolaryngol Head Neck Surg Date: 2011-11
Authors: Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Raghav C Dwivedi; Edward J Chisholm; Afroze S Khan; Nicholas J Harris; Shree A Bhide; Suzanne St Rose; Cyrus J Kerawala; Peter M Clarke; Christopher M Nutting; Peter H Rhys-Evans; Kevin J Harrington; Rehan Kazi Journal: Eur Arch Otorhinolaryngol Date: 2011-09-10 Impact factor: 2.503
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Klaudia U Hunter; Oliver E Lee; Teresa H Lyden; Marc J Haxer; Felix Y Feng; Mathew Schipper; Francis Worden; Mark E Prince; Scott A McLean; Gregory T Wolf; Carol R Bradford; Douglas B Chepeha; Avraham Eisbruch Journal: Head Neck Date: 2013-06-01 Impact factor: 3.147
Authors: Rico N Rinkel; Irma M Verdonck-de Leeuw; Patricia Doornaert; Jan Buter; Remco de Bree; Johannes A Langendijk; Neil K Aaronson; C René Leemans Journal: Eur Arch Otorhinolaryngol Date: 2015-06-14 Impact factor: 2.503
Authors: V C Sandulache; Y L Lei; L E Heasley; M Chang; C I Amos; E M Sturgis; E Graboyes; E Y Chiao; N Rogus-Pulia; J Lewis; A Madabhushi; M J Frederick; A Sabichi; M Ittmann; W G Yarbrough; C H Chung; R Ferrarotto; Weiyuan Mai; H D Skinner; U Duvvuri; P Gerngross; A G Sikora Journal: Oral Oncol Date: 2019-10-22 Impact factor: 5.337
Authors: Jorine A Vermaire; Cornelis P J Raaijmakers; Evelyn M Monninkhof; C René Leemans; Robert J Baatenburg de Jong; Robert P Takes; Irma M Verdonck-de Leeuw; Femke Jansen; Johannes A Langendijk; Chris H J Terhaard; Caroline M Speksnijder Journal: Support Care Cancer Date: 2022-08-30 Impact factor: 3.359
Authors: Nedeljko Jovanovic; Colleen Dreyer; Sarah Hawkins; Kendra Thouless; David Palma; Philip C Doyle; Julie A Theurer Journal: Support Care Cancer Date: 2020-08-01 Impact factor: 3.603
Authors: Rebecca T Karsten; Najiba Chargi; Lisette van der Molen; Rob J J H van Son; Remco de Bree; Abrahim Al-Mamgani; Jan P de Boer; Frans J M Hilgers; Michiel W M van den Brekel; Ludi E Smeele; Martijn M Stuiver Journal: Eur Arch Otorhinolaryngol Date: 2021-05-27 Impact factor: 2.503
Authors: M Sean Peach; Daniel M Trifiletti; Carolyn Vachani; Karen Arnold-Korzeniowski; Christina Bach; Margaret Hampshire; James M Metz; Christine E Hill-Kayser Journal: Patient Relat Outcome Meas Date: 2018-07-27